Braxia Scientific announces participation in the annual growth conference Canaccord Genuity 2021 from August 10th to 12th


TORONTO, August 6, 2021 / PRNewswire / – Braxia Scientific Corp. (“Braxia” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics offering innovative ketamine treatments for people with depression and related conditions, is pleased to to announce its participation in the upcoming Canaccord Genuity Annual Growth Conference. The conference will take place virtually on 10.-12. August 2021.

Braxia Scientific Managing Director Dr. Roger McIntyre will give a presentation on the company’s initiatives to develop novel therapeutics and delivery systems for the treatment of depression and other brain-based diseases, and to manage patient care within its network of clinics.

Presentation details:
Date: Tuesday, August 10, 2021
Time: 11:30 p.m. ET
Event registration:

You can find more information about the conference HERE.

About Braxia Scientific Corp.

Braxia Scientific is a medical research company with clinics providing innovative ketamine treatments for people with depression and related conditions. With its medical solutions, Braxia aims to reduce the burden of disease caused by brain-based mental disorders such as major depressive disorders. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics that provide treatment for mental disorders and (ii) research activities related to the discovery and commercialization of novel drugs and delivery methods. Braxia aims to develop ketamine and derivatives as well as other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics that provide fast-acting treatments for depression Mississauga, Toronto, Ottawa, and Montreal.


“DR. Roger S. McIntyre
DR. Roger S. McIntyre

The CSE has not reviewed this press release and assumes no responsibility for the accuracy or appropriateness of this press release.

Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, projections, projections, goals, assumptions, expectations or beliefs of future performance are “forward-looking statements”.

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential of ketamine to treat other emerging psychiatric disorders, such as bipolar depression. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to differ materially from future results, events or developments expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the failure of ketamine, psilocybin, and other psychedelics to achieve the expected health benefits and unexpected side effects, reliance on obtaining and maintaining government approvals, including the acquisition and renewal of federal, provincial, , Township, municipal or other licenses, and engaging in activities that may later be classified as illegal under national or international law. Ketamine and psilocybin are currently under the Controlled Drugs and Substances Act, SC 1996, c. 19 (the “CDSA”) and it is a criminal offense to possess such substances as defined by the CDSA without a prescription or statutory exception. Health Canada has not approved psilocybin as a drug for any indication, but ketamine is a legally approved drug for the treatment of certain mental illnesses. It is illegal to possess such substances Canada without recipe.

Careful consideration should be given to these factors and readers are cautioned not to place undue reliance on such forward-looking statements.

Although the company has attempted to identify important risk factors that could cause actual actions, events, or results to differ materially from those described in any forward-looking statements, other risk factors could cause actions, events, or results to differ from those anticipated. estimated or intended. Additional information to help identify risks and uncertainties that could affect financial results is included in the company’s filings with Canadian securities regulators, including the amended and revised listing dated April 15, 2021available at There can be no assurance that forward-looking statements will prove to be correct, as actual results and future events could differ materially from those anticipated in the forward-looking statements.

Cision View original content to download multimedia: .html

SOURCE Braxia Scientific Corp.


Comments are closed.